17:25 , Jun 29, 2018 |  BC Week In Review  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor...
00:23 , Jun 26, 2018 |  BC Extra  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN) on Monday. The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4;...
20:01 , Feb 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other molecule...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters that...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker klotho...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

NGM313: Phase I started

NGM began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single and multiple ascending doses of NGM313 in about 183 healthy overweight or obese volunteers. NGM is developing NGM313 for conditions that include Type...
08:00 , Jan 10, 2013 |  BC Innovations  |  Cover Story

mAb about FGF21

Amgen Inc. has developed an antibody that mimics fibroblast growth factor 21 and has antidiabetic effects in monkeys.1 The findings cap a year of advances that have greatly increased understanding of the protein's tissue-specific actions,...
08:00 , Dec 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Fibroblast growth factor receptor 1 (FGFR1; CD331); klotho-b (KLB); fibroblast growth...
07:00 , Oct 11, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Fibroblast growth factor receptor 1 (FGFR1; CD331), FGFR2 and fibroblast growth factor 19 (FGF19) amplification may help predict sensitivity to FGFR...